18 articles

Our Vascular surgeon Dr Manar Khashram has been awarded the Te Whatu Ora Waikato Kudos Medical Scientist award 2023

  • 5 December 2023

One of the most prominent trials conducted by Dr Khashram and CTNZ includes the management of abdominal aortic aneurysms. Congratulations Dr Khashram from the team at CTNZ.

Prevision study with PI Dr Manar Khashram

  • 3 May 2023

Our Clinical Trials NZ vascular team has been conducting Prevision study with PI Dr Manar Khashram.

A pilot randomised controlled trial of oral doxycycline after endoscopic sinus surgery and its effects on the sinonasal microbiome.

  • 17 January 2023

Challis JM, Baptista MS, Ragupathy R, Lee CK, Wood AJ. Rhinology Online. 2022; 5: 49-61


  • 10 November 2022

Melbourne, Australia

2023 ARCS Annual Conference (6 – 8 June 2023)

  • 10 November 2022

The 2023 ARCS Annual Conference (6 – 8 June 2023) will be held at the International Convention Centre (ICC), Darling Harbour, Sydney.

9th VERVE Symposium in Sydney in December

  • 10 November 2022


VEITHsymposium November 2022

  • 6 August 2022

49th Annual Symposium on Vascular and Endovascular Issues

Do you have Plaque Psoriasis?

  • 9 September 2019

Clinical Trials NZ is conducting a clinical trial of an investigational medication for moderate to severe Plaque Psoriasis.

Clinical Feasibility Study for Endovenous Deep Vein Valve Formation for Chronic Venous Insufficiency

  • 18 June 2019

Initial Results. Mr. Thodur Vasudevan, Clinical Trials NZ

Type 2 Diabetes Study

  • 10 November 2017

Type 2 Diabetes Study

Severe Rosacea Study

  • 21 February 2017

Do you suffer from Rosacea? Clinical Trials NZ in Hamilton is conducting a clinical trial with a new medication for people who have Rosacea (Red Flushing Face).

Upcoming NZ Acres 2017 Conference

  • 20 February 2017

The theme for the conference this year is “Innovation in Research and Clinical Trials”.

SABER™ Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control...

  • 15 October 2014

demonstrates dose-response, safety and no impact on surgical wound healing.

SABER™ Bupivacaine Reduces Postoperative Pain Intensity and Opioid Use for 72 Hours in Soft-Tissue and Bony Surgeries

  • 15 October 2014

Poster presentation American Society of Anaesthesiologists, October 15 2014

Intranasal Ketorolac (ROX-888) for Postoperative Pain: A Phase 3, Double-Blind, Randomized Study

  • 8 May 2008

Presented at the 2008 Society for Ambulatory Anesthesia Annual Meeting